Main menu

Applications of nanopore sequencing in precision cancer medicine

Cancer invading
Return to ResourcesRead the full text
  • Published on: July 19 2024
  • Source: International Journal of Cancer
Authors: Sergey A. Dyshlovoy, Stefanie Paigin, Ann-Kristin Afflerbach, Annabelle Lobermeyer, Stefan Werner, Ulrich Schüller, Carsten Bokemeyer, Anna H. Schuh, Lina Bergmann, Gunhild von Amsberg, Simon A. Joosse

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust

© 2008 - 2026 Oxford Nanopore Technologies plc. All rights reserved. Registered Office: Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK | Registered No. 05386273 | VAT No 336942382. Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, EPI2ME, GridION, MinION, MinKNOW, PromethION, P2 Solo, and P2 are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may be protected by copyright, patents or patents pending of Oxford Nanopore Technologies plc. All other brands and names contained are the property of their respective owners. Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in‐vitro diagnostic devices in some jurisdictions, please check individual product labelling.

ONT plc is a member of the producer compliance scheme run by ERP UK Ltd, who manage the submission of documentation in support of WEEE compliance for ONT plc’s manufacture and supply of Electrical and Electronic equipment in the UK.

ONT’s WEEE PRN is WEE/MM3828AA. See attached certificate for the submission period 2022.

English flag